Research
Hormonal
Incretin-based therapies (GLP-1 and dual/triple agonists) produce clinically significant weight loss (15-21%) and improve cardiometabolic, renal, and hepatic outcomes, marking a turning point in obesity management.
Current GLP-1 and dual agonist medications are highly effective for significant weight loss and improving overall health markers like heart and liver function. They represent a major advancement over lifestyle changes alone, though they require long-term commitment and management of potential side effects like nausea.
StrongSupportsVERY_HIGH confidence
The rapid development of highly effective incretin-based therapies has transformed obesity care by achieving clinically significant and substantial weight loss... Incretin-based therapy demonstrates substantial weight loss while also improving cardiometabolic, renal, hepatic, and functional outcomes.
Why this rating
Based on multiple Phase 3 trials (STEP, SURMOUNT, etc.) with large sample sizes and robust statistical significance.
Source
Future Directions in the Medical Treatment of Obesity: A Narrative Review
Aya Bassatne et al. · Advances in Therapy · 2026
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →